← Back to screener

Roivant Sciences Ltd. ROIV

Rank #235 · Nasdaq · $26.5B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
71.8
P/E
6.1
P/B
5.66
ROE
92.8%
Op. Margin
13746.9%
Debt Ratio
5%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★★☆☆
Good

P/E 6.1x, P/B 5.66x. Ranks in the top 35% of the universe.

Profitability ★★★★★
Excellent

ROE 92.8%. Ranks in the top 2% of the universe.

Safety ★★★★★
Excellent

Debt ratio 5%. Ranks in the top 8% of the universe. Under 100% is generally considered a safe level.

Growth ★★☆☆☆
Average

Revenue growth of 3.8% year over year. Ranks in the top 53% of the universe.

Profitability is the relative strength · Growth is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2022$0.0B$-1.1B$-0.8B$1.8B-4500.529
2023$0.1B$-1.2B$-1.0B$1.2B-1917.968
2024$0.0B$-0.9B$-1.0B$6.0B-2875.913
2025$0.0B$4.5B$4.3B$4.7B13746.95

← See the full screener